In a patient with chronic constipation currently taking prucalopride 2 mg twice daily and bixilat 10 mg before dinner, what additional therapy should be prescribed for abdominal fullness and to further improve constipation?

Critical Dosing Error: Reduce Prucalopride Immediately

You are prescribing prucalopride at twice the FDA-approved maximum dose—this must be corrected immediately to 2 mg once daily, not twice daily. 1

Immediate Action Required

1. Correct the Prucalopride Dosing Error

• Maximum approved dose: 2 mg once daily (not twice daily) 2, 1
• Your current regimen of 2 mg twice daily (4 mg total) exceeds the approved dose
• The FDA label explicitly states the recommended dose is 2 mg once daily for adults with CIC 1
• Reduce to 2 mg once daily immediately

2. For Abdominal Fullness: Add Linaclotide or Plecanatide

I recommend adding linaclotide 145-290 mcg once daily OR plecanatide 3 mg once daily to specifically address the abdominal fullness. 2

Rationale for secretagogues:

• Both linaclotide and plecanatide have demonstrated benefit for abdominal pain and bloating/distension in addition to constipation 2
• Prucalopride primarily improves bowel frequency and may help with abdominal symptoms, but secretagogues have more robust evidence for concurrent abdominal symptoms 2, 3
• These agents work through different mechanisms (guanylate cyclase-C agonists vs 5-HT4 agonist), providing complementary effects

Specific dosing:

• Linaclotide: Start 145 mcg daily, can increase to 290 mcg daily based on response 2
• Plecanatide: 3 mg once daily (fixed dose) 2

3. Continue Bixibat as Currently Prescribed

• Bixibat 10 mg before dinner is appropriate and can be continued
• This bile acid modulator works through a different mechanism and can be used in combination

Clinical Algorithm for This Patient

Step 1: Correct prucalopride to 2 mg once daily (from current 4 mg/day)

Step 2: Add a secretagogue for abdominal fullness:

• First choice: Linaclotide 145 mcg daily (better evidence for abdominal symptoms)
• Alternative: Plecanatide 3 mg daily if linaclotide not tolerated or unavailable

Step 3: Continue bixibat 10 mg before dinner

Step 4: Reassess in 4 weeks:

• If constipation improved but abdominal fullness persists: Increase linaclotide to 290 mcg daily
• If inadequate response overall: Consider adding polyethylene glycol 17 g daily as adjunctive therapy 2

Important Safety Considerations

Prucalopride Warnings

• Monitor for suicidal ideation and behavior - the FDA label includes a warning about unusual mood changes 1
• Most common side effects: headache, abdominal pain, nausea, diarrhea (typically transient, occurring in first week) 2
• Diarrhea leading to discontinuation occurs in ~3% of patients 2

Secretagogue Warnings

• Diarrhea is the main limiting side effect - occurs in a subset of patients leading to discontinuation 2
• Start with lower dose of linaclotide (145 mcg) to minimize this risk
• Take on empty stomach, 30 minutes before first meal of the day

Combination Therapy Pitfall

Common mistake: Using multiple agents from the same class simultaneously

• Your current regimen appropriately uses agents from different classes (5-HT4 agonist + bile acid modulator)
• Adding a secretagogue provides a third complementary mechanism
• This multi-mechanistic approach is supported for refractory cases 4, 5

Why This Specific Recommendation

The 2023 AGA-ACG guidelines provide strong evidence that:

1. Prucalopride 2 mg once daily (not higher) improves bowel frequency with moderate-to-high certainty evidence 2
2. Secretagogues specifically address abdominal symptoms that prucalopride may not fully resolve 2
3. Prucalopride improved abdominal symptoms in trials, but effect sizes were larger for stool symptoms than abdominal symptoms 3, 6
4. Combination therapy is appropriate when monotherapy fails, using agents with different mechanisms 4

The abdominal fullness suggests incomplete symptom control, warranting addition of an agent with proven efficacy for this specific symptom rather than simply increasing an already supra-therapeutic prucalopride dose.